Spatial omics has progressively evolved into a crucial tool for research on the cardiovascular system and cardiovascular diseases, uncovering the spatial and molecular heterogeneity that underpins cardiac function and pathology. Spatial omics remains an emerging technology with tremendous development prospects. The future prospects of spatial omics technologies are illustrated in Fig.
3. Future advancements in sequencing technology will likely improve spatial resolution, sequencing depth, and detection throughput at both single-cell or subcellular levels (Fig.
3A). Currently, there are studies combining spatial omics with other multi-omics technologies [
3]. These technologies are extensively utilized in oncology research, including studies on gastric cancer [
213], lung cancer [
214], and breast cancer [
215]. In the cardiovascular field, some studies have integrated spatial omics with single-cell assay for transposase-accessible chromatin (sc-ATAC) data [
112,
136]. However, research that combines multiple spatial omics datasets remains relatively limited. With the introduction of more multiomics integration platforms, it is reasonable to believe that spatial multiomics will be more widely applied in the future (Fig.
3B). In addition, spatial multiomics detection in tissues or even in vivo can directly address sample losses during acquisition and preparation. Currently, the emergence of nanorobots offers new possibilities for automation in in vivo or in situ spatial multiomics research (Fig.
3C). Drug research can also benefit from spatial multiomics technology, revealing the pharmacokinetics, pharmacodynamics, and toxicological effects of drugs (Fig.
3D). AI has numerous applications in the biomedical field, including deep learning-based microfluidic organs-on-chips (OoCs) [
216], deep graph learning models for identifying ligandable covalent sites [
217], drug research at the single-cell level [
218], protein function prediction [
219] and structural analysis [
220], as well as direct analysis via DIA [
221]. With the development of AI, the complex steps of spatial omics technology are expected to become automated in the future, reducing costs and improving efficiency (Fig.
3E). Spatial multiomics has been widely used to explore the microenvironment, especially in the field of tumor microenvironments [
222]. In the cardiovascular field, Kanemaru et al. [
112] discovered unique microecological structures in the sinoatrial node and the marked “signal hub” role of macrophages in the human epicardial immune microecology. As the importance of precision medicine and prevention is increasingly recognized, identifying individualized therapeutic targets will be a primary focus in future clinical practice, where single-cell omics and spatial omics provide great potential. We propose that spatial multiomics may discover spatially characteristic individualized “spatial targets” in the future (Fig.
3F). The novel concept of “spatial targets” is defined as niches of therapeutically relevant molecules, metabolites, or cells organized spatially.